CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 37 enrolled
Drug / intervention
Faster-acting insulin aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01999322
NCT01999322Phase 3Completed
CompareCT.gov

A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

Novo Nordisk A/S·interventional·Posted Dec 3, 2013·Updated Oct 31, 2017

In Brief

A Phase 3 clinical trial evaluating Faster-acting insulin aspart and insulin aspart for Diabetes and Diabetes Mellitus, Type 1. Completed, enrolled 37 participants across 2 sites in 2 countries.

Detailed Summary

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®) with an external continuous subcutaneous insulin infusion (CSII) system in adult subjects with type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 1
CountriesGermany, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 3, 2013
Enrollment StartNov 19, 2013
Primary CompletionMay 14, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.6 years ago

Interventions

Faster-acting insulin aspartdrug

Administered subcutaneously (s.c., under the skin). Dose individually adjusted.

insulin aspartdrug

Administered subcutaneously (s.c., under the skin). Dose individually adjusted.